USFDA’s new draft biosimilar rules to benefit Indian biotech cos
The US Food and Drug Administration’s (USFDA)’s new draft guidelines aimed at speeding up and reducing the cost of developing biosimilars — lower-priced, near-replicas of complex biologic medicines — could significantly benefit Indian biotech companies. Photograph: Srdjan Zivulovic/Reuters The new

